Moffitt Cancer Center study suggests more could benefit from CAR T-cell therapy

(H. Lee Moffitt Cancer Center & Research Institute) Moffitt Cancer Center organized a consortium of 16 cancer treatment facilities across the US that offer Yescarta as a standard-of-care therapy for patients with relapsed/refractory large B cell lymphoma. They wanted to determine if the safety and effectiveness seen in the ZUMA-1 clinical trial were similar for patients treated with the now commercially available CAR T therapy. Their findings were published in the Journal of Clinical Oncology.